Details

Autor(en) / Beteiligte

• Li, Dapeng
• Martinez, David R
• Schäfer, Alexandra
• Chen, Haiyan
• Barr, Maggie
• Sutherland, Laura L
• Lee, Esther
• Parks, Robert
• Mielke, Dieter
• Edwards, Whitney
• Newman, Amanda
• Bock, Kevin W
• Minai, Mahnaz
• Nagata, Bianca M
• Gagne, Matthew
• Douek, Daniel C
• DeMarco, C Todd
• Denny, Thomas N
• Oguin, 3rd, Thomas H
• Brown, Alecia
• Rountree, Wes
• Wang, Yunfei
• Mansouri, Katayoun
• Edwards, Robert J
• Ferrari, Guido
• Sempowski, Gregory D
• Eaton, Amanda
• Tang, Juanjie
• Cain, Derek W
• Santra, Sampa
• Pardi, Norbert
• Weissman, Drew
• Tomai, Mark A
• Fox, Christopher B
• Moore, Ian N
• Andersen, Hanne
• Lewis, Mark G
• Golding, Hana
• Seder, Robert
• Khurana, Surender
• Baric, Ralph S
• Montefiori, David C
• Saunders, Kevin O
• Haynes, Barton F

Titel

Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine

Ist Teil von

• Nature communications, 2022-10, Vol.13 (1), p.6309-15, Article 6309

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2022

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Coronavirus vaccines that are highly effective against current and anticipated SARS-CoV-2 variants are needed to control COVID-19. We previously reported a receptor-binding domain (RBD)-sortase A-conjugated ferritin nanoparticle (scNP) vaccine that induced neutralizing antibodies against SARS-CoV-2 and pre-emergent sarbecoviruses and protected non-human primates (NHPs) from SARS-CoV-2 WA-1 infection. Here, we find the RBD-scNP induced neutralizing antibodies in NHPs against pseudoviruses of SARS-CoV and SARS-CoV-2 variants including 614G, Beta, Delta, Omicron BA.1, BA.2, BA.2.12.1, and BA.4/BA.5, and a designed variant with escape mutations, PMS20. Adjuvant studies demonstrate variant neutralization titers are highest with 3M-052-aqueous formulation (AF). Immunization twice with RBD-scNPs protect NHPs from SARS-CoV-2 WA-1, Beta, and Delta variant challenge, and protect mice from challenges of SARS-CoV-2 Beta variant and two other heterologous sarbecoviruses. These results demonstrate the ability of RBD-scNPs to induce broad neutralization of SARS-CoV-2 variants and to protect animals from multiple different SARS-related viruses. Such a vaccine could provide broad immunity to SARS-CoV-2 variants.